AbstractsGastrointestinal tumours, non-colorectal155O - Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s
Gastrointestinal tumours, non-colorectal
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.